Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures. Because the inhibition of noradrenaline reuptake may be expected to increase systolic and diastolic blood pressure (SBP and DBP) and pulse rate (PR), a 12-week multi-centre, placebo-controlled, double-blind study was designed to evaluate the efficacy and tolerability of sibutramine for weight loss in obese patients whose hypertension was well controlled (DBP р95 mm Hg) by ␤-adrenergic blocking agents (␤-blockers), with or without concomitant thiazide diuretics. Of the 61 patients randomised to sibutramine 20 mg once daily or placebo, 55 patients (90%) completed the study. After 12 weeks, sibutramine-treated patients lost significantly more weight than placebo-treated patients: mean weight reductions were 4.2 kg (4.5%) in the sibutramine group vs 0.3 kg (0.4%) in the placebo group (P Ͻ0.001). Greater weight reduction on sibutramine was accompanied by trends for greater mean reductions in serum triglycerides and very low density lipoprotein cholesterol. Sibutramine was well tolerated, and most adverse events were mild or moderate in severity. No sibutramine patient discontinued treatment because of an adverse event. Mean supine and standing DBP and SBP were not
Introduction
Obesity is an important risk factor for developing hypertension and is a confounding factor in the effective treatment of hypertension. Weight reduc-statistically significantly different between the sibutramine group and the placebo group at any post-baseline visit during the 12-week trial. At week 12, mean increases from baseline supine SBP and DBP, respectively, were 1.6 and 1.7 mm Hg for the sibutramine group vs increases of 0.4 and 1.3 mm Hg for the placebo group. At week 12, mean increases from baseline standing SBP and DBP, respectively, were 1.5 and 1.8 mm Hg for the sibutramine group vs an increase of 0.3 and a decrease of 0.8 mm Hg for the placebo group (P Ͼ 0.05 for treatment comparison). A statistically significant mean increase of 5.6 bpm (؎8.25, s.d.) in supine PR from a baseline of 62 bpm was reported in sibutraminetreated patients at week 12, whereas placebo-treated patients had a mean supine PR decrease of 2.2 bpm (؎6.43) (P Ͻ 0.001). In summary, sibutramine was well tolerated and effective in weight reduction. The addition of sibutramine did not result in an increase in BP in obese patients whose hypertension was well controlled by a ␤-blocker. However, based on the potential for changes in BP and PR, obese patients being treated with sibutramine should be monitored periodically for changes in BP and PR and managed appropriately. tion has been shown to have a favourable impact on the risk of hypertension and its management. [1] [2] [3] Sibutramine (sibutramine hydrochloride monohydrate; Meridia  , Reductil  ) taken orally once daily enhances satiety and produces significant, dose-related weight reduction in obese patients when used as an adjunct to dietary and behavioural measures. [4] [5] [6] At doses of 5 to 20 mg once daily, sibutramine is safe and well tolerated, and weight
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reduction is maintained while treatment continues. 7 The current recommended dosage of sibutramine is 10 or 15 mg once daily.
Sibutramine is a tertiary amine that undergoes demethylation in the liver, generating two active metabolites with potent inhibitory activity on serotonin and noradrenaline reuptake. 8, 9 Its mechanism as a serotonin-noradrenaline reuptake inhibitor is distinct from the mechanisms of fenfluramine, dexfenfluramine, and the amphetamines. Sibutramine and its metabolites do not stimulate neuronal monoamine release, lack the abuse potential associated with amphetamines, 8, 10, 11 and have not been associated with the cardiovascular pathologies which have been seen with fenfluramine. 12, 13 Both preclinical and clinical studies strongly suggest that dopamine is not a target for sibutramine at pharmacologically relevant concentrations. 8, 10, 11, 14 Consistent with its enhancement of noradrenergic activity relative to placebo, normotensive obese patients on sibutramine treatment have experienced small mean increases in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Increases of 1 to 3 mm Hg and increases in pulse rate (PR) of 4 to 5 beats per minute (bpm) at doses up to 20 mg have been reported. 8 In a dose-ranging study, at a sibutramine treatment dose of 15 mg, the current maximum recommended dose, changes in BP (+2.7 mm Hg, SBP; +3.4 mm Hg, DBP) were not statistically significantly different from BP changes observed with placebo treatment. 5 In recent, large, placebo-controlled trials with sibutramine, however, the numbers of patients in whom an increase in BP became clinically significant, or in whom mild hypertension appeared, leading to withdrawal from treatment, were generally not significantly different between sibutramine-and placebo-treated patients. 6, 7, [15] [16] [17] The objective of this study was to evaluate the efficacy of sibutramine on weight loss, BP, and PR in hypertensive obese patients whose BP was well controlled by stable doses of a ␤-adrenergic blocking agent (␤-blocker). This study was part of a series of three studies evaluating the efficacy and tolerability of sibutramine in patients with hypertension well controlled with angiotensin-converting enzyme inhibitors, calcium channel blockers, or ␤-blockers. Based on results available at the time of design of the studies, a dose of 20 mg was selected for evaluation, which is higher than the maximum 15 mg dose currently recommended.
Materials and methods

Study design
This was a 12-week, double-blind, placebo-controlled, parallel-group, randomised study in obese patients whose hypertension was well controlled with a ␤-blocker, with or without concomitant thiazide diuretic therapy. The study was carried out at five clinical research centres. The Institutional Review Board at each centre approved the protocol, and all patients gave oral and written informed consent prior to participation.
At the initial screening visit, a physical examination was conducted, height and weight measured, body mass index (BMI) calculated, a 12-lead electrocardiogram (ECG) recorded, supine and standing BP and PR measured, and blood and urine samples collected for routine laboratory evaluations. Qualifying patients entered a single-blind, 2-week minimum run-in period, during which placebo medication was dispensed to the patients, who were instructed to take one capsule each morning. Run-in visits were separated by a minimum of 7 days. Enrolment was limited to patients whose hypertension was well controlled. Eligible patients were randomised into the 12-week, double-blind phase of the study. Patients randomised to sibutramine were titrated from 5 to 20 mg once daily in 5-mg increments per week. Patients were given a standardised programme of dietary advice with exercise and behavioural recommendations.
At each run-in visit, the baseline randomisation visit, and weeks 1, 2, 3, 4, 8, and 12, BP and PR were measured, adverse events and concomitant medications were documented, and weight (except at the run-in visits) was measured. At the baseline visit, a 12-lead ECG was recorded. At week 12, or at the time of premature termination of treatment, a physical examination was performed, a 12-lead ECG was recorded, and samples were collected for laboratory evaluations. Haematology, serum chemistry (including lipid profile), and urinalysis were performed at screening and week 12. Serum pregnancy tests were performed at screening, baseline, and week 12, when appropriate.
Supine and then standing BP and PR were measured after 5 min supine and 1 min standing, respectively. At all visits, measurements of supine and standing BP and PR were taken, from which average values were calculated. BP was measured after PR. If a patient developed a mean increase in supine PR Ͼ20 bpm over the baseline mean PR, or if PR was Ͼ105 bpm at any visit during the study, the protocol mandated that the patient be discontinued from the study.
Safety and adverse events were monitored at each visit or as reported. Adverse events were recorded according to the COSTART classification system. 18 A study design flowchart is shown in Figure 1 .
Patients
Male and female hypertensive patients у18 years of age with a BMI from 27 to 40 kg/m 2 were eligible to participate in this study. Patients had to have been diagnosed with hypertension у12 months before the screening visit, and they must have had a mean DBP р95 mm Hg that was well controlled. Patients were defined as having well-controlled DBP if their mean supine DBP did not fluctuate у10 mm Hg over three consecutive visits of the run-in period, if individual measurements within each visit during the run-in period stayed within a 10-mm Hg range, and if they had no dosage changes in either the ␤-blocker or thiazide diuretic during the run-in period. Patients could also be taking a fixed maintenance dose of a potassium-sparing diuretic, potassium supplements, or lipid-lowering agents along with the ␤-blocker.
Patients were excluded from the study if their hypertension was secondary to a concurrent medical condition (other than obesity) or drug therapy. Patients with a mean supine PR Ͼ95 bpm at baseline or a mean supine DBP Ͼ95 mm Hg at any run-in visit were also excluded. A history of convulsions, severe cerebral trauma, stroke, significant endocrine abnormalities, a significant history of cardiac disease, or any clinically significant abnormal cardiac condition other than hypertension was also cause for exclusion. In addition, patients with clinically significant laboratory abnormalities or a history of gastric surgery to reduce obesity were excluded, as were those who had participated in a weight loss programme within 3 months prior to the screening visit.
Statistical analyses
The study was powered to determine a difference of 3 kg in weight loss between treatment groups. Based on previous studies, this would require a sample size of 30 patients per treatment group. Statistical tests were two-tailed at the P Ͻ 0.05 level of significance. Inferential analyses on continuous variables were done using a two-way analysis of variance procedure. Repeated measure analysis was not used, and the treatment groups were compared at each scheduled visit. The normality of residuals was assessed using the Shapiro-Wilk procedure, and homogeneity of variance was tested using Levene's Journal of Human Hypertension procedure. The Wilcoxon test for two samples was used for comparison of changes in lipid profile. Analysis of categoric data was done using the Cochran-Mantel-Haenszel test. Discontinued patients were included in most analyses until the time of their withdrawal. Unless noted otherwise, continuous variables are presented as mean (± standard deviation).
Results
Patient demographics and disposition
A total of 61 eligible patients were randomised into the study, 29 to sibutramine and 32 to placebo. Fiftyfive patients (90%) completed the 12-week study. Hypertension in all randomised patients was well controlled (DBP р95 mm Hg) with a ␤-blocker. Atenolol was the ␤-blocker most frequently used, being taken by 59% of the sibutramine group and 63% of the placebo group. In addition, 62% of the sibutramine-treated patients and 69% of placebotreated patients were also receiving thiazide diuretics. Baseline and demographic characteristics of randomised patients, including supine DBP and SBP and PR, are shown in Table 1 . No statistically significant differences were found between the sibutramine and placebo treatment groups at baseline.
Weight loss efficacy
After 12 weeks of treatment, body weight in patients treated with sibutramine had decreased by a mean of 4.2 kg (±3.8), or 4.5% (±4.0), compared to 0.3 kg (±2.0), or 0.4% (±2.0), for placebo-treated patients (P Ͻ 0.001 for both total weight lost and percentage of body weight lost, all randomised patients). At the follow-up visit 10-14 days after treatment was stopped, patients in the sibutramine treatment group had maintained a weight reduction of −3.5 kg (±4.25)
Journal of Human Hypertension compared to maintenance of −0.5 kg (±2.23) for placebo treatment (P Ͻ 0.01). Patients in the sibutramine treatment group also experienced a greater mean percentage weight reduction from baseline than the placebo treatment group at all time points. The difference between the treatment groups was statistically significant from week 2 (P Ͻ 0.01) to week 12 (P р 0.001) and at the follow-up visit, when patients were no longer on treatment for obesity (P Ͻ 0.01). The mean percentage decreases in weight from baseline during the course of the study are shown in Figure 2 . Patients in the sibutramine treatment group also had a greater mean decrease in BMI at all time points from week 2 (P р 0.002) compared to placebo. At week 12, patients in the sibutramine treatment group had a mean reduction in BMI of 1.5 kg/m 2 (±1.3) compared to a mean reduction of 0.1 (±0.7) for placebo (P Ͻ 0.001, all randomised patients). The sibutramine treatment group had greater mean decreases in BMI at all time points, and these decreases were significantly greater than those seen with placebo from weeks 2-12 (P р 0.002, all randomised patients).
Greater weight loss over 12 weeks in patients on sibutramine treatment was generally accompanied by greater mean changes in lipid profile, including greater reductions in serum triglycerides and very low density lipoprotein (VLDL) cholesterol levels and greater increases in high-density lipoprotein (HDL) cholesterol levels. However the trends favouring sibutramine treatment did not reach statistical significance in this modestly sized trial.
Increases and decreases in BP and heart rate
No statistically significant differences in supine or standing DBP or SBP were found between the sibutramine and placebo groups at any post-baseline visit during the 12-week double-blind trial. Mean changes in supine DBP during the 12-week doubleblind treatment period ranged from a decease of 1.2 to an increase of 1.7 mm Hg for the sibutramine group and from a decrease of 1.1 to an increase of 1.3 mm Hg for the placebo group. Mean changes in postural DBP ranged from a decrease of 0.4 to an increase of 1.8 mm Hg for the sibutramine group and from a decrease of 1.3 to an increase of 1.4 mm Hg for the placebo group (P Ͼ 0.05). Mean changes in supine SBP ranged from a decrease of 2.3 to an increase of 1.6 mm Hg for sibutramine-treated patients (95% CI, −2.99, 6.19) and from a decrease of 3.1 to an increase of 0.6 mm Hg for placebo-treated patients (95% CI, −3.59, 4.39; P Ͼ 0.05). Mean changes in standing SBP ranged from a decrease of 1.1 to an increase of 2.3 mm Hg for the sibutramine group and from a decrease of 0.2 to an increase of 3.3 mm Hg for the placebo group. At week 12, mean increases from baseline supine SBP and DBP, respectively, were 1.6 and 1.7 mm Hg for the sibutramine group vs 0.4 and 1.3 mm Hg for the placebo group. At week 12, mean increases from baseline standing SBP and DBP, respectively, were 1.5 and 1.8 mm Hg for the sibutramine group vs an increase of 0.3 and a decrease of 0.8 mm Hg for the placebo group (P Ͼ 0.05 for treatment comparison). None of the above treatment comparisons for supine BP were statistically significant (P Ͼ 0.05).
Mean supine PR for the sibutramine and placebo treatment groups at baseline was 62.2 and 63.9 bpm, respectively, indicating that patients were on average treated adequately with ␤-blockers. Mean increases and decreases from baseline supine PR during the study are shown in Figure 3 . The data presented in Figure 3 possibly suggest an upward trend for heart rate over time among patients treated with sibutramine. Statistically significant differences in mean supine PR for sibutramine-treated patients compared to placebo-treated patients were found at weeks 4, 8, 12 , and at the follow-up visit (P р 0.022). Mean PR at week 12 were sibutramine treatment, 67.1 bpm and placebo treatment, 61.5 bpm (difference, 5.6 bpm; P Ͻ 0.01 sibutramine compared with placebo). One patient in the sibutramine treatment group had a PR increase Ͼ20 bpm to 74 bpm from baseline (52 bpm) at week 4. This patient was allowed to remain in the study, as no deleterious effects were noted, and subsequent PR changes in this patient were Ͻ20 bpm throughout the remainder of the study. No statistically significant increases or decreases in mean postural PR were found in either treatment group during the study.
Mean heart rates calculated from ECG readings were consistent with the findings of treatmentrelated increases in PR. At week 12, the changes in ECG heart rate for individual patients in each treatment group ranged from a decrease of 8.0 to an increase of 25.0 bpm for the sibutramine treatment group and ranged from a decrease of 18.0 to an increase 15.0 bpm for the placebo treatment group. No possibly clinically significant abnormal values for heart rate (р50 bpm with a у15 bpm decrease from baseline or у120 bpm with a у15 bpm increase from baseline) occurred. No conduction abnormalities were observed on ECG readings during the study.
Safety
Sibutramine was safe and well tolerated during the 12-week trial. Adverse events occurring in у10% of patients in at least one treatment group are shown in Table 2 . Overall, adverse events were reported by 93% (27/29) of the patients receiving sibutramine and 87.5% (28/32) of those receiving placebo, the difference between the groups not being statistically significant. The most common adverse events reported by patients in the sibutramine treatment group were dry mouth and headache, but the rate of their reporting was not statistically significantly different from the rate in the placebo treatment group. Most adverse events reported were mild to moderate in intensity. Clinical laboratory evaluations did not reveal any changes indicative of a deleterious treatment effect.
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No patients in the sibutramine group discontinued treatment because of adverse events. Three patients receiving placebo treatment (9%) were discontinued from the study because of adverse events (diarrhoea, pancreatitis, and pharyngitis).
Discussion
In the present 12-week study, sibutramine was found to be an effective weight loss agent, with statistically significant reductions observed within 2 weeks of treatment initiation in absolute weight, percent reduction from baseline weight, and BMI compared to placebo. At week 12, a mean 4.5% reduction from baseline weight was observed in patients treated with sibutramine 20 mg once daily compared to a 0.4% reduction for placebo treatment (P р 0.001, all randomised patients). In a previous 24-week dose-ranging study in normotensive obese patients, weight loss at week 12 in patients on sibutramine 20 mg once daily was 5.7% of body weight. 7 These losses are comparable to those observed with the treatment duration in the present study, indicating that the concomitant use of ␤-blockers does not appear to diminish the efficacy of the compound.
Sibutramine, a monoamine neurotransmitter reuptake inhibitor, inhibits food intake by promoting satiety via the synergistic interaction of increased serotonergic and noradrenergic activity in the central nervous system. 8, 14 Additionally, sibutramine has been shown to increase energy utilisation. 19, 20 The increased energy utilisation activity of sibutramine may be indirectly generated by central stimulation of efferent sympathetic output to the ␤ 3 -adrenoceptors in brown adipose tissue. 20, 21 Increase in energy expenditure with sibutramine treatment has been reported in two studies 19, 20 Journal of Human Hypertension although not in one other. 22 This possible dual mechanism of action may enhance the efficacy of sibutramine by diminishing the decrease in metabolic rate normally encountered upon initial weight loss. Because the cardiovascular side effects of sibutramine can be attributed, in part, to stimulation of the sympathetic nervous system, blocking of the cardiac ␤ 1 -adrenoceptors with ␤-blockers can be expected to reduce the magnitude of these effects. Most patients in this study were taking atenolol, a ␤-blocker with specificity for ␤ 1 -adrenoceptors. Although this compound penetrates the central nervous system poorly and thus would not be expected to counteract the central adrenergic effects of sibutramine, ␤ 1 -adrenoceptor blockade in the periphery might reduce sympathetic cardiovascular effects while not disrupting any potential, beneficial, possibly ␤ 3 -receptor-mediated peripheral effects of sibutramine. Some evidence exists that nonselective ␤-adrenoceptor blockade during treatment for hypertension can result in decreased energy utilisation and weight gain, 23, 24 which could complicate the interpretation of the results of this study. While this study did not specifically compare patients treated with ␤-blockers to those not so treated, this study shows that sibutramine produces significant weight loss in overweight patients taking ␤-blockers, a mainstay of treatment for hypertension. It is interesting to note that atenolol effectively prevented the modest increase in BP that can be seen with the use of sibutramine, but atenolol did not appear to prevent the increase in PR. The reason for the differing effects is not known. A recently published report 25 assessing the effect of sibutramine on sympathetic and parasympathetic activity showed the expected increase in sympathetic activity. It did not show a diminution in parasympathetic control.
In the present study, although the 20-mg dose of sibutramine was greater than the 15-mg maximum daily dose currently recommended for clinical use, the increases in BP observed in these obese hypertensive patients taking ␤-blockers were not statistically significant. The PR increases, however, were significant. At week 12, the mean increase in PR over the baseline value of 62 bpm was 5.6 bpm, a statistically significantly greater increase than that seen in the placebo group (P Ͻ 0.01). These results differ from those observed in a previous study, a 52-week placebo-controlled trial of sibutramine given at a 10-mg dose, 6 in which the increases in PR in normotensive individuals treated with sibutramine were generally not significantly different from the PR changes seen in the placebo group. However, another study of sibutramine given at the 20-mg once daily for 24 weeks 15 reported statistically significant increases in DBP (5.0 mm Hg) and PR (7.0 bpm) compared with placebo (P Ͻ 0.05).
The present study shows that hypertension controlled through ␤-adrenoceptor blockade in obese individuals remains well controlled when weight is lost with sibutramine treatment. The increase in sympathetic activity induced by sibutramine could possibly counteract the normal BP-lowering effect of weight loss. On the other hand, the small increases in BP and PR may be offset by reductions in other risk factors achieved by more efficient weight loss with sibutramine, such as improvement in lipid profiles seen in this and other studies. [4] [5] [6] 15 Nevertheless, because BP and PR changes may occur as a result of the pharmacologic activity of sibutramine, these parameters should be periodically monitored during treatment. Sibutramine is not recommended for use in patients with uncontrolled or poorly controlled hypertension, nor in patients with a history of serious cardiovascular disease (coronary artery disease, cardiac arrhythmia, congestive heart failure, or stroke). 26 Rates of reported adverse events in this study were not statistically different for the sibutramine treatment group compared to the placebo treatment group.
In summary, this study indicates that sibutramine is an effective, well-tolerated weight management agent in obese patients and does not exacerbate preexisting hypertension controlled with ␤-blockers. Although the effects of sibutramine on decreasing BP may not be entirely commensurate with the extent of the weight loss achieved, obesity itself has recently been recognised as a major, independent, modifiable risk factor for coronary heart disease, 27 and weight loss and the maintenance of weight are clearly superior when adjunctive sibutramine therapy is used. [6] [7] [8] [15] [16] [17] 28 In the present study, improvements associated with weight loss resulting from sibutramine use included greater improvement in BMI, greater reduction in serum triglyceride and VLDL cholesterol, and increase in HDL cholesterol. Greater improvements in lipids paralleled greater weight loss, as reported previously. [4] [5] [6] 15 Despite the presence of apparently effective ␤-adrenoceptor blockade, modest increases in PR were observed in sibutramine-treated obese hypertensive patients in the present study, perhaps suggesting that mechanisms other than increased sympathetic tone may, at least in part, mediate this effect. Based on the potential for increases in BP and PR, obese patients with well-controlled hypertension who are treated for weight loss with sibutramine should be monitored periodically for possible BP and PR effects.
